Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases

Strahlentherapie und Onkologie

Volumn 190, Issue 7, 2014, Pages 676-685

  Berghoff, A S ^a,b   Ilhan Mutlu, A ^b   Wohrer A ^a,b   Hackl, M ^c   Widhalm, G ^b   Hainfellner, J A ^a,b   Dieckmann, K ^b   Melchardt, T ^d   Dome, B ^b   Heinzl, H ^b   Birner, P ^b   Preusser, M ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Austrian National Cancer Registry   (Austria)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Angiogenesis; Hypoxia; Proliferation; Survival; Whole brain radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROSURGERY; OVERALL SURVIVAL; PROTEIN EXPRESSION;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KI-67 ANTIGEN; MALE; MICROVESSELS; MIDDLE AGED; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903395328     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0639-8     Document Type: Article

References (42)

1. Yamanaka R (2009) Medical management of brain metastases from lung cancer (Review). Oncol Rep 22:1269-1276
2. Sperduto PW et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425
3. Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751 (Pubitemid 27181303)
4. Sperduto PW et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510-514
5. Rades D et al (2013) A new survival score for patients with brain metastases from non-small cell lung cancer. Strahlenther Onkol 189:777-781
6. Huang C et al (2005) Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92:1231-1239 (Pubitemid 40604397)
7. Trivella M et al (2007) Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 8:488-499 (Pubitemid 46805904)
8. Yohena T et al (2009) Upregulation of hypoxia-inducible factor-1 alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol 4:284-290
9. Park S et al (2011) Prognostic implications of hypoxia-inducible factor-1 alpha in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 72:100-107
10. Kim SJ et al (2005) Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325-335 (Pubitemid 41139145)
11. Wohrer A et al (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95:401-411
12. Preusser M et al (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39-47 (Pubitemid 351861984)
13. Birner P et al (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133-143 (Pubitemid 36460814)
14. Zhong H et al (1999) Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59:5830-5835
15. Cappuzzo F et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655 (Pubitemid 40812628)
16. Hirsch FR et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807 (Pubitemid 46606235)
17. Spanberger T et al (2013) Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metastasis 30:357-368
18. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169-180
19. Heinzl H (2000) Using SAS to calculate the Kent and O'Quigley measure of dependence for Cox proportional hazards regression model. Comput Methods Programs Biomed 63:71-76
20. Kent J, Quigley J (1988) Measures of dependence for censored survival data. Biometrika 75:525-534
21. Bender R, Lange S (2001) Adjusting for multiple testing-when and how? J Clin Epidemiol 54:343-349
22. Radovic S et al (2007) Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors. Bosn J Basic Med Sci 7:205-211
23. Saad AG et al (2008) Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 113:2129-2138
24. Giatromanolaki A et al (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179:80-88 (Pubitemid 26180086)
25. Medetoglu B et al (2010) Tumor angiogenesis in predicting the survival of patients with stage I lung cancer. J Thorac Cardiovasc Surg 140:996-1000
26. Kreuter M et al (2009) Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 33:1383-1388
27. Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21:107-112
28. Pezzella F et al (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417-1423 (Pubitemid 27479772)
29. Kienast Y et al (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16:116-122
30. Mangili F et al (1998) Cell loss and proliferation in non-small cell lung carcinoma: correlation with histological subtype. Eur J Histochem 42:287-295 (Pubitemid 29096901)
31. Guo S et al (2012) Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer 77:389-393
32. Collaud S et al (2012) Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer 78:234-238
33. De Ruysscher D et al (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 7:1547-1555
34. Hu C et al (2006) Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106:1998-2004 (Pubitemid 43673216)
35. Nieder C et al (2007) The role of postoperative radiotherapy after resection of a single brain metastasis. Combined analysis of 643 patients. Strahlenther Onkol 183:576-580 (Pubitemid 47482159)
36. Nieder C et al (1998) Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlenther Onkol 174:275-278 (Pubitemid 28237142)
37. Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141
38. Monaco EA 3rd et al (2013) Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 119:226-232
39. Soffietti R et al (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31:65-72
40. Rades D, Schild SE (2012) Do patients with a limited number of brain metastases need whole-brain radiotherapy in addition to radiosurgery? Strahlenther Onkol 188:702-706
41. Bachtiary B et al (2003) Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9:2234-2240 (Pubitemid 36687648)
42. Sperduto CM et al (2008) A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg 109(Suppl):87-89